Biomarkers predict progressive spinal harm in ankylosing spondylitis By Laura Cowen German experts can see five biomarkers that might predict the progression of structural harm in the backbone of individuals with ankylosing spondylitis who already are at risky for disease progression. The results, provided at the European Little league Against Rheumatism Annual Congress of Rheumatology in Berlin, Germany, show that degrees of matrix metalloproteinase 3, bone-morphogenetic protein 2, procollagen type II N-propeptide , vascular endothelial development element , and osteoprotegerin are connected with AS structural harm click to read more .
Does which means that that they are not overvalued now – a correction has occurred and that biotech stocks are actually priced right already? Or can be biotech still over-priced, and much more so now perhaps? If this is the case, exactly why is it the case? What good may result from overvaluing any stock? Long-term, there is normally nothing good that may come from currency markets overvaluation, in virtually any sector. Consider the tech bubble of 2000 or the casing and toxic mortgage loan burst in 2007 that resulted in the fantastic Recession.